• Androgen Deprivation Therapy (ADT): suppression/blockade of testosterone production/action.

  • Aromatase Inhibitor (AI): blocks aromatase (CYP19A1) → ↓ estrogen (anastrozole/letrozole/exemestane).

  • Selective Estrogen Receptor Modulator (SERM): tamoxifen—ER antagonist in breast, partial agonist in bone/endometrium.

  • Selective Estrogen Receptor Degrader (SERD): fulvestrant—binds ER and triggers degradation.

  • CYP17A1: androgen-synthesis enzyme targeted by abiraterone.

  • Gonadotropin-Releasing Hormone (GnRH): hypothalamic hormone controlling LH/FSH (agonists/antagonists suppress gonadal steroids).

  • DiHydroEpiAndrosterone (DHEA): androgen precursor supplement; avoid during endocrine therapy.

  • International Prostate Symptom Score (IPSS): urinary symptom scale, 0–35.

  • Intrauterine Device (IUD), Copper: non-hormonal contraception of choice during endocrine therapy.

  • Osteonecrosis of the Jaw (ONJ): serious antiresorptive complication—avoid implants/extractions on therapy.

  • RECIST v1.1: imaging response criteria.

  • Dual-Energy X-ray Absorptiometry (DEXA): bone mineral density scan.

  • EORTC QLQ-C30, SF-36, FACT-P: validated QoL instruments (oncology general, general health, prostate-specific).

  • ESR1/AR-V7: mutations/variants associated with endocrine resistance.